Biozone Pharmaceuticals, Inc. (OTCBB:BZNE): $3 Million Worth of Shares Sold

It seems nobody wants Biozone Pharmaceuticals, Inc. (OTCBB:BZNE) and is rather eager to shed about 8 million shares in two days. BZNE sank just about 4%, but selling volumes hit a record at more than $3.13 million. Currently, BZNE stands at $0.565 and awaits a verdict on whether it would develop, or sink back into obscurity and negligible volumes. [[tagnumber 0]] [[tagnumber 1]]The ticker is weighed down by big investors who are right now the only ones capable of generating powerful enough volumes to sway the price. That, plus the lack of promotion, means BZNE may be controlled a bit too well for serendipitous results. [[tagnumber 2]][[tagnumber 3]] [[tagnumber 1]]Still, BZNE may have longer–term appeal, as it is a consumer good company that has gained appeal with several big investors. While BZNE does not announce huge profits, so far it is active and operational, holding the following financials:[[tagnumber 3]] [[tagnumber 6]] [[tagnumber 7]]$354, 471 cash [[tagnumber 8]] [[tagnumber 9]] [[tagnumber 6]] [[tagnumber 7]]$8 million total assets [[tagnumber 8]] [[tagnumber 9]] [[tagnumber 6]] [[tagnumber 7]]$10.4 million total current liabilities [[tagnumber 8]] [[tagnumber 9]] [[tagnumber 6]] [[tagnumber 7]]$1.9 million sales for last quarter [[tagnumber 8]] [[tagnumber 9]] [[tagnumber 6]] [[tagnumber 7]]$729,756 quarterly net loss [[tagnumber 8]] [[tagnumber 9]] [[tagnumber 1]]The company produces consumer OTC medicines and cosmetics, and uses a patented cosmetic technology for delivering active compounds, which it also offers to third party producers. Unfortunately, last year BZNE was hurt by a drug recall.[[tagnumber 3]] [[tagnumber 1]]So far, BZNE has mostly been seen around the Internet through its regular SEC filings. Another piece of news could continue the interest. But BZNE is entering a new era of activity, so it is still a wait and see.[[tagnumber 3]] [[tagnumber 1]]Pharmaceuticals wonders often burst on the trading screen among the most active micro cap or small cap stocks.[[tagnumber 31]] But those fast movers often cause great distress with deep corrections. One of the recent climbers was NanoViricides, Inc. (OTCMKTS:NNVC). The antiviral drug company doubled in price in August and September, but is now down from $7 and toward $5 on another steep shakedown.[[tagnumber 3]] [[tagnumber 1]]And while Advanced Cell Technology, Inc. (OTCMKTS:ACTC) rode for a while the fame of controversial scientist Robert Lanza, the stock also deflated, and struggled between 5 and 7 cents in the past couple of months, just now running a small breakthrough.[[tagnumber 3]] [[tagnumber 1]]While there are no guaranteed scenarios, it is best to stay away from BZNE unless you can afford erratic movements.[[tagnumber 3]]